NIH $2.3M Ibogaine Study Sets Strict Heart Safety Limits

In a first of it’s kind ibogaine trial for opioid addiction in America, every participant will wear a heart monitor around the clock. One number will determine whether researchers keep going.

If a participant’s QTc interval rises above 500 milliseconds or climbs 20 percent above baseline researchers will stop the dose. The QTc interval measures the heart’s electrical activity and can signal dangerous arrhythmias.

That safety rule anchors a National Institute on Drug Abuse cooperative agreement worth about $2.3 million over two years for Brigham and Women’s Hospital in Boston. Total funding could reach roughly $11 million according to Medical Daily. Researchers designed the trial in response to deaths linked to ibogaine use outside laboratory settings.

Why Ibogaine Raises Cardiac Concerns

Ibogaine is a Schedule I substance in the United States. Federal law doesn’t allow its use outside approved research, which has pushed people seeking the treatment toward clinics across the Mexican border.

Tijuana providers charge about $8000 per treatment. People with opioid addiction have traveled there seeking relief from withdrawal and cravings. Some are employed professionals who can afford the trip.

The risks aren’t theoretical, a 2015 study linked ibogaine treatment to a fatality rate near one in 400. Cardiac events played a role in several deaths.

The 500 Millisecond Limit

The trial starts with healthy volunteers that receive single doses of ibogaine that gradually increase, while researchers monitor their heart function with inpatient electrocardiograms.

Once that stage meets its safety requirements, researchers will enroll people with opioid use disorder who haven’t responded to buprenorphine and have never taken ibogaine. Blinded assessors will rate the outcomes to help reduce bias.

The strict cardiac limits reflect what researchers already know about the drugs involved. Methadone can prolong the QT interval and adding ibogaine could intensify that effect. The trial therefore sets 500 milliseconds as a firm limit.

Federal agencies have also taken new steps toward psychedelic research this year. An executive order in April urged agencies to speed research into psychedelics for mental health and addiction. NIDA has funded ibogaine studies including a planned University of Arizona trial focused on traumatic brain injury.

Noribogaine has also entered the research pipeline. The ibogaine derived compound received approval in April for a study involving people with alcohol use disorder. That study marks the first US trial of an ibogaine derivative.

These developments don’t change ibogaine’s legal status. The Brigham trial still needs FDA Investigational New Drug clearance before researchers can give the first dose.

Current Detox Options

Doctors already have several established options for opioid addiction. Medically supervised withdrawal management buprenorphine methadone and naltrexone all have substantial safety data behind them.

Ibogaine could eventually join that group but researchers first need to show that clinicians can use it without causing a dangerous cardiac event.

If you’re considering detox now, a medically supervised program gives you access to medical monitoring and support. Cardiac monitoring can matter more for people with higher health risks. Long term alcohol dependence also deserves special attention because withdrawal can trigger seizures.

Don’t stop prescribed medications, such as methadone or buprenorphine to pursue unregulated ibogaine treatment abroad.

Call 800-996-6135Sponsored to discuss medical detox options with a specialist. You can also reach SAMHSA’s National Helpline at 1-800-662-4357 or search detox.com’s directory for detox centers near you.